The power of a clinical trial to test drug efficacy is related directly to the effect size of its outcome measures, their precision and their sensitivity to drug-associated changes. The initial trials of diseasemodifying therapies rapidly demonstrated the power of conventional magnetic resonance imaging (MRI) measures (counts of gadolinium-enhancing and T2 lesions) to detect changes with anti-inflammatory treatments. Their acceptance as meaningful was enhanced by post mortem correlative studies directly relating the imaging measures to neuropathological 'gold standard' criteria for white matter inflammatory lesions. 1 Subsequent demonstrations that they could be related directly to the clinically meaningful outcomes of relapse frequency and time to sustained disability progression transformed perceptions of the utility of these measures for the clinical development of anti-inflammatory treatments. 2 This history is a reminder that a useful clinical trial endpoint measure as one that is 1. Able to be related to the concept of interest (in this case, active white matter inflammatory lesions); 2. Able to be measured on multiple platforms and by different observers; 3. Sensitive to treatment-related change; and, 4. Clinically meaningful (i.e. in terms of the way that a person with disease feels or functions).
Any measure introduced into a clinical trial comes at a cost. The cost can be in terms of time, inconvenience, risk or direct expense. Cost also is incurred in a clinical trial by the complication or delay of decisionmaking by introducing uncertainties of interpretation. The latter introduces a necessary 'biomarker conservatism' into clinical trials: we should not make measurements in clinical trials without a plan for using the data meaningfully. 3 This does not mean that exploratory measures should not be used. However, when this is done, they need to be recognised as such.
What do we know about measures derived from the two newer MRI methods in question here: blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI)? BOLD fMRI is based on generating a statistical image describing significant increases in the local susceptibility weighted MRI signal arising from increases in the (diamagnetic) oxygenated blood volume that accompany neuronal activation in the healthy brain. 4 This so-called 'haemodynamic response' is mediated by signalling from neurons to astrocytes and then from astrocytes to pre-capillary sphincters controlling local capillary dilation. Thus, while BOLD fMRI may reflect local increases in synaptic activity, the measure is several steps removed from its direct assessment.
DTI is based on a simpler idea. Water molecules diffuse in all directions equally in bulk liquids (e.g. ventricular cerebrospinal fluid (CSF)), but with the physical constraints to free diffusion provided by cell membranes, water in tissue has preferred directions of diffusion, for example, with 'fast' diffusion along the membranes of myelinated axons, rather than across them. DTI is sensitive to this directionality (anisotropy) of diffusion. Water diffusion along tightly packed, well-oriented myelinated axonal tracts, such as those in the spinal cord, is highly anisotropic with preferential diffusion parallel to the principle axis of the axons. Demyelination or axonal degeneration is associated with locally increased diffusion orthogonal to the original axis of the tract. 5 Both of these methods are powerful research tools. In conjunction with other data, they have provided major new insights concerning the functional organisation of the brain and its dynamics in health and disease. 6 Early studies with fMRI in multiple sclerosis (MS) provided compelling evidence (since supported by many additional observations) that functional reorganisation of the brain is an important mechanism of PM Matthews functional recovery after axonal loss with inflammatory demyelination. 7 Applications of DTI have complemented other experimental measures of demyelination and axonal loss, particularly as they provide measures related to the progressive loss of brain connectivity with disease progression. 8 They have been powerful tools for generating hypotheses regarding clinico-pathological correlations.
Nonetheless, they have substantial limitations for testing hypotheses, particularly in the context of MS.
The phenomena that they are sensitive to are only related indirectly to the concepts of real interest. This can lead to fundamental confounds to interpretation. For example, fMRI depends on the comparability of neurovascular coupling mechanisms in health and disease, in different stages of disease or with treatment. Astrocyte activation state and the microvasculature can be altered in MS. 9 Differences therefore may reflect the influences of MS pathology (or possible drug effects) on the neurovascular coupling mechanism rather than on neuronal activation.
For DTI, the issues are different, but the general conclusion is similar. Interpretation of DTI measures in cerebral white matter depends on an understanding of the tissue microstructure that we cannot have in the context of the evolving neuropathology of MS. The maximum practical linear resolution of a singleimage voxel (>1 mm 3 ) is so much larger than the cross-sectional area of individual axons (<5 µm 3 ) that diffusion measures are always averaged across many fibres. In contrast to the spinal cord, where axons are highly linearly oriented, cerebral white matter has a complex microanatomy of crossing or angulated fibres through most of its volume. Diffusion along orthogonal crossing fibres averaged within the same voxel may not display significant anisotropy, despite the highly oriented diffusion in each. Loss or dystrophy of axons in either component of such orthogonal crossing fibres will give rise to a 'paradoxical' increase in diffusion fractional anisotropy. 10 At the whole voxel level, this would be similar to what might be anticipated with remyelination! The measures also have fundamentally limited measurement properties. Both fMRI and DTI intrinsically generate much lower signals than does conventional MRI, as only small fractions of the total water in the tissue are being used to generate the image signal. Unless the effect sizes for the phenonmenon of interest scale similarly, the measures may not improve the efficiency of a Phase II trial. As they are most commonly implemented, they are also expressed as relative, rather than absolute measures. Hence, it is difficult to interpret changes in the measures in terms of absolute changes in the brain tissue. This makes comparisons of results across disease stages (or different forms of pathology) problematic, as the contexts for normalisation change.
None of this is to suggest that fMRI and DTI are not powerful tools for characterisation of in vivo neuropathology or for exploratory pharmacology (e.g. following demonstration of drug-associated changes in the same measures in an animal model). However, as relative measures of MRI biophysical phenomena are only indirectly related to the functional neuropathology of interest, with sensitivities to relevant drug responses that are uncharacterised or based on only relatively small clinical studies, these measures are far from 'clinical trial ready'. Contextualising BOLD fMRI signals using simultaneous measures of baseline blood flow and neurovascular reactivity and advanced data acquisition and analytics for DTI could address some of the concerns that I have raised. 9 However, with the exception of classical evoked potential measures, these tools still are at very early stages of development.
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A number of paraclinical outcome measures have been used in multiple sclerosis (MS) clinical studies in addition to clinical endpoints to monitor disease progression and treatment efficacy. In this context, magnetic resonance imaging (MRI)-based measures are of paramount relevance due to their sensitivity in detecting and quantifying the focal and diffuse pathology occurring in MS. 1 Indeed, MRI measures of white matter lesional activity (i.e. new/enlarging T2 lesions or Gd-enhancing T1 lesions) and those of brain atrophy (i.e. percentage of brain volume change) have shown to be valid surrogate endpoints for clinical outcomes and have been accepted as endpoints in the most recent pharmacologic clinical trials. 2 In addition to these MRI measures, newer and more tissue-specific MRI measures able to assess the microscopic tissue damage (e.g. magnetization transfer imaging (MTI), diffusion tensor imaging (DTI)) and the functional cortical reorganization (i.e. functional magnetic resonance imaging (fMRI)) occurring in the brain of MS patients have been proposed. In these controversies in MS, Kapoor advocates that these advanced MRI metrics should be outcome measures in future clinical trials, while Matthews counters that, at present, they have limited practical utility and are far from being 'clinical trial ready'.
As correctly indicated by Kapoor, while we have efficient MRI biomarkers able to surrogate MS relapse and the related inflammation (i.e. active lesions), the situation looks much more confused when the aim becomes the assessment of disease progression and the related neurodegeneration. In this context, we agree that measurement of brain atrophy is not and cannot be the solution, as this represents a sort of global measure of various mechanisms of tissue injury that is influenced by a complex interplay across multiple cellular compartments. Biomarkers that are specific for tissue injury and repair are therefore necessary to provide more pathologically specific endpoints. The main question is: can MRI provide these biomarkers in the near future?
There is no doubt that most of the advanced MRI methods, including DTI and fMRI, are powerful research tools that have shed a new light into MS and its pathogenetic mechanisms (i.e. altered brain connectivity and changes in functional reorganization). We may also agree, as stressed by Kapoor, that these MRI techniques
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